Kosin Med J.  2022 Dec;37(4):283-290. 10.7180/kmj.22.106.

Correlation of long interspersed element-1 open reading frame 1 and c-Met proto-oncogene protein expression in primary and recurrent colorectal cancers

• Jeon KY
• Ko EJ
• Chang HK
• Lee SH
• Ahn BK
• Ock MS
• Cha HJ

• KMID: 2538859
• DOI: http://doi.org/10.7180/kmj.22.106

Abstract

Background
Colorectal cancer is one of the most common cancers worldwide. Colorectal cancer that has recurred and metastasized to other organs also has a very poor prognosis. According to recent studies, the long interspersed element-1 (LINE-1) retrotransposon open reading frame (ORF) is located in the intron of the c-Met proto-oncogene, which is involved in cancer progression and metastasis, and regulates its expression. However, no study has compared the expression patterns of LINE-1 ORF1 and c-Met, which are closely related to cancer progression and metastasis, and their correlation in primary and recurrent cancers.
Methods
In the present study, we compared the expression patterns of LINE-1 ORF1 and c-Met in both primary and recurrent colorectal cancer tissues from 10 patients. Expression patterns and correlations between LINE-1 ORF1 and c-Met proto-oncogene proteins were analyzed by immunofluorescence staining using both LINE-1 ORF1 and c-Met antibodies.
Results
The expression patterns of LINE-1 ORF1 and c-Met showed significant individual differences, and the expression of both proteins was correlated in all colorectal cancer patients. However, the expression levels of LINE-1 ORF1 and c-Met were not significantly different between primary and recurrent colorectal cancers.
Conclusions
The protein expression levels of LINE-1 ORF1 and c-Met were correlated, but did not change significantly in cases of recurrent colorectal cancer in the same patient.

Keyword

Colorectal neoplasms; Primary; Recurrent; Long interspersed element-1 open reading frame 1(LINE-1 ORF 1, L1 ORF 1); c-Met

Figure

• 

  Fig. 1. Expression patterns of LINE-1 (L1) ORF1 and c-Met in each patient. The 10 patient colorectal cancer sample slides underwent immunofluorescence analysis. For each patient, two samples were used: primary and recurrent colorectal cancers. Ten spots were captured in each slide. Images were captured with LSM510 software at ×400 magnification. LINE-1, long interspersed element-1 retrotransposon; ORF, open reading frame.

• 

  Fig. 2. Expression levels of LINE-1 ORF1 and c-Met in each patient’s primary and recurrent colorectal cancer sample. The horizontal axis of the graph is patient number, and the vertical axis is the expression level confirmed by the integrated density value (IDV) of the image. (A) Expression of LINE-1 ORF1 in each patient. (B) Expression of c-Met in each patient. LINE-1, long interspersed element-1 retrotransposon; ORF, open reading frame.

• 

  Fig. 3. Overall expression patterns of LINE-1 ORF1 and c-Met in primary and recurrent colorectal cancers. The horizontal axis of the graph indicates either primary or recurrent colorectal cancer, and the vertical axis is the level of expression confirmed by the integrated density value (IDV) of the image. (A) Expression of LINE-1 ORF1 in primary and recurrent colorectal cancer. (B) Expression of c-Met in primary and recurrent colorectal cancer. LINE-1, long interspersed element-1 retrotransposon; ORF, open reading frame.

• 

  Fig. 4. Correlation analysis of LINE-1 ORF1 and c-Met expression patterns. The expression of LINE-1 ORF1 and c-Met was correlated in all panels. The correlation was calculated using SPSS software. (A) Correlation of LINE-1 ORF1 and c-Met expression in primary colorectal cancer. (B) Correlation of LINE-1 ORF1 and c-Met expression in recurrent colorectal cancer. (C) Correlation of LINE-1 ORF1 and c-Met expression across all colorectal cancers. IDV, integrated density value; LINE-1, long interspersed element-1 retrotransposon; ORF, open reading frame.

Reference

References

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127:2893–917.

2. Labianca R, Beretta GD, Kildani B, Milesi L, Merlin F, Mosconi S, et al. Colon cancer. Crit Rev Oncol Hematol. 2010; 74:106–33.

3. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014; 383:1490–502.

4. Jalili-Nik M, Soltani A, Moussavi S, Ghayour-Mobarhan M, Ferns GA, Hassanian SM, et al. Current status and future prospective of Curcumin as a potential therapeutic agent in the treatment of colorectal cancer. J Cell Physiol. 2018; 233:6337–45.

5. Kang YJ, Jo JO, Ock MS, Chang HK, Lee SH, Ahn BK, et al. Thymosin β4 was upregulated in recurred colorectal cancers. J Clin Pathol. 2014; 67:188–90.

6. Chen L, Dahlstrom JE, Chandra A, Board P, Rangasamy D. Prognostic value of LINE-1 retrotransposon expression and its subcellular localization in breast cancer. Breast Cancer Res Treat. 2012; 136:129–42.

7. Hur K, Cejas P, Feliu J, Moreno-Rubio J, Burgos E, Boland CR, et al. Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto-oncogenes in human colorectal cancer metastasis. Gut. 2014; 63:635–46.

8. Mima K, Nowak JA, Qian ZR, Cao Y, Song M, Masugi Y, et al. Tumor LINE-1 methylation level and colorectal cancer location in relation to patient survival. Oncotarget. 2016; 7:55098–109.

9. Speek M. Antisense promoter of human L1 retrotransposon drives transcription of adjacent cellular genes. Mol Cell Biol. 2001; 21:1973–85.

10. Nigumann P, Redik K, Matlik K, Speek M. Many human genes are transcribed from the antisense promoter of L1 retrotransposon. Genomics. 2002; 79:628–34.

11. Khalid M, Bojang P Jr, Hassanin AA, Bowers EC, Reyes-Reyes EM, Ramos IN, et al. Line-1: implications in the etiology of cancer, clinical applications, and pharmacologic targets. Mutat Res Rev Mutat Res. 2018; 778:51–60.

12. Martin SL. Ribonucleoprotein particles with LINE-1 RNA in mouse embryonal carcinoma cells. Mol Cell Biol. 1991; 11:4804–7.

13. Holmes SE, Singer MF, Swergold GD. Studies on p40, the leucine zipper motif-containing protein encoded by the first open reading frame of an active human LINE-1 transposable element. J Biol Chem. 1992; 267:19765–8.

14. Hohjoh H, Singer MF. Sequence-specific single-strand RNA binding protein encoded by the human LINE-1 retrotransposon. EMBO J. 1997; 16:6034–43.

15. Hohjoh H, Singer MF. Cytoplasmic ribonucleoprotein complexes containing human LINE-1 protein and RNA. EMBO J. 1996; 15:630–9.

16. Khazina E, Weichenrieder O. Non-LTR retrotransposons encode noncanonical RRM domains in their first open reading frame. Proc Natl Acad Sci U S A. 2009; 106:731–6.

17. Feng Q, Moran JV, Kazazian HH Jr, Boeke JD. Human L1 retrotransposon encodes a conserved endonuclease required for retrotransposition. Cell. 1996; 87:905–16.

18. Wolff EM, Byun HM, Han HF, Sharma S, Nichols PW, Siegmund KD, et al. Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet. 2010; 6:e1000917.

19. Mathias SL, Scott AF, Kazazian HH Jr, Boeke JD, Gabriel A. Reverse transcriptase encoded by a human transposable element. Science. 1991; 254:1808–10.

20. Dombroski BA, Feng Q, Mathias SL, Sassaman DM, Scott AF, Kazazian HH Jr, et al. An in vivo assay for the reverse transcriptase of human retrotransposon L1 in Saccharomyces cerevisiae. Mol Cell Biol. 1994; 14:4485–92.

21. Drongitis D, Rainone S, Piscopo M, Viggiano E, Viggiano A, De Luca B, et al. Epigenetics and cortical spreading depression: changes of DNA methylation level at retrotransposon sequences. Mol Biol Rep. 2016; 43:755–60.

22. Burns KH. Transposable elements in cancer. Nat Rev Cancer. 2017; 17:415–24.

23. Rodic N, Sharma R, Sharma R, Zampella J, Dai L, Taylor MS, et al. Long interspersed element-1 protein expression is a hallmark of many human cancers. Am J Pathol. 2014; 184:1280–6.

24. Swets M, Zaalberg A, Boot A, van Wezel T, Frouws MA, Bastiaannet E, et al. Tumor LINE-1 methylation level in association with survival of patients with stage II colon cancer. Int J Mol Sci. 2016; 18:36.

25. Miglio U, Berrino E, Panero M, Ferrero G, Coscujuela Tarrero L, Miano V, et al. The expression of LINE1-MET chimeric transcript identifies a subgroup of aggressive breast cancers. Int J Cancer. 2018; 143:2838–48.

26. Park M, Dean M, Kaul K, Braun MJ, Gonda MA, Vande Woude G. Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc Natl Acad Sci U S A. 1987; 84:6379–83.

27. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003; 4:915–25.

28. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 2003; 22:309–25.

29. Kammula US, Kuntz EJ, Francone TD, Zeng Z, Shia J, Landmann RG, et al. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett. 2007; 248:219–28.

30. Boccaccio C, Comoglio PM. MET, a driver of invasive growth and cancer clonal evolution under therapeutic pressure. Curr Opin Cell Biol. 2014; 31:98–105.

31. Chen T, Cai SL, Li J, Qi ZP, Li XQ, Ye LC, et al. Mecp2-mediated epigenetic silencing of miR-137 contributes to colorectal adenoma-carcinoma sequence and tumor progression via relieving the suppression of c-Met. Sci Rep. 2017; 7:44543.

32. Scheri KC, Leonetti E, Laino L, Gigantino V, Gesualdi L, Grammatico P, et al. c-MET receptor as potential biomarker and target molecule for malignant testicular germ cell tumors. Oncotarget. 2018; 9:31842–60.

33. Zhang J, Babic A. Regulation of the MET oncogene: molecular mechanisms. Carcinogenesis. 2016; 37:345–55.

34. Di Renzo MF, Olivero M, Giacomini A, Porte H, Chastre E, Mirossay L, et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res. 1995; 1:147–54.

35. Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, Dietrich S, et al. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer. 2008; 47:1025–37.

36. Zeng ZS, Weiser MR, Kuntz E, Chen CT, Khan SA, Forslund A, et al. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett. 2008; 265:258–69.

37. Boromand N, Hasanzadeh M, ShahidSales S, Farazestanian M, Gharib M, Fiuji H, et al. Clinical and prognostic value of the C-Met/HGF signaling pathway in cervical cancer. J Cell Physiol. 2018; 233:4490–6.

38. Luo Y, Ouyang J, Zhou D, Zhong S, Wen M, Ou W, et al. Long noncoding RNA GAPLINC promotes cells migration and invasion in colorectal cancer cell by regulating miR-34a/c-MET signal pathway. Dig Dis Sci. 2018; 63:890–9.

39. Zhu C, Utsunomiya T, Ikemoto T, Yamada S, Morine Y, Imura S, et al. Hypomethylation of long interspersed nuclear element-1 (LINE-1) is associated with poor prognosis via activation of c-MET in hepatocellular carcinoma. Ann Surg Oncol. 2014; 21 Suppl 4:S729–35.